Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer
Globe Newswire (Tue, 10-Feb 8:00 AM ET)
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 3-Feb 8:00 AM ET)
Globe Newswire (Mon, 26-Jan 8:00 AM ET)
Globe Newswire (Tue, 6-Jan 8:00 AM ET)
Business Wire (Wed, 17-Dec 5:00 PM ET)
Milestone’s CARDAMYST Approval Delivers First Self-Administered PSVT Solution in Over 30 Years
Market Chameleon (Mon, 15-Dec 4:55 AM ET)
Globe Newswire (Fri, 12-Dec 8:00 PM ET)
Globe Newswire (Wed, 12-Nov 7:01 AM ET)
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
Milestone Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol MIST.
As of February 10, 2026, MIST stock price climbed to $1.84 with 2,005,956 million shares trading.
MIST has a beta of 2.35, meaning it tends to be more sensitive to market movements. MIST has a correlation of 0.12 to the broad based SPY ETF.
MIST has a market cap of $156.71 million. This is considered a Micro Cap stock.
Last quarter Milestone Pharmaceuticals - Common Shares reported $0 in Revenue and -$.12 earnings per share. This fell short of revenue expectation by $-400,000 and exceeded earnings estimates by $.05.
In the last 3 years, MIST traded as high as $4.49 and as low as $.63.
The top ETF exchange traded funds that MIST belongs to (by Net Assets): QQQS, GWX.
MIST has underperformed the market in the last year with a price return of -14.4% while the SPY ETF gained +16.4%. However, in the short term, MIST had mixed performance relative to the market. It has outperformed in the last 3 months, returning +7.6% vs +3.4% return in SPY. But in the last 2 weeks, MIST shares have been beat by the market, returning -5.2% compared to an SPY return of -0.1%.
MIST support price is $1.75 and resistance is $1.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MIST shares will trade within this expected range on the day.
